SEC Filing Summary: Klotho Neurosciences, Inc. (KLTO)
Business Context and Reporting Period
Company: Klotho Neurosciences, Inc. (formerly ANEW Medical, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: A pre-revenue biopharmaceutical company developing essential medicines for chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. The company operates two primary platforms: a biosimilar biologics platform (acquired from Reliance Life Sciences) and a proprietary gene therapy platform targeting the "Klotho" protein for neurodegenerative diseases (licensed from Universitat Autònoma de Barcelona).
Corporate Structure: The company completed a reverse acquisition business combination with Redwoods Acquisition Corp. on June 21, 2024. For accounting purposes, ANEW Medical is the accounting acquirer. The company is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6,150,372) | $(707,458) |
| Operating Expenses | $5,540,236 | $631,322 |
| Cash and Cash Equivalents (End of Period) | $63,741 | $2,808 |
| Working Capital | $(1,089,723) | $(1,614,341) |
| Total Assets | $2,457,365 | $2,192,706 |
| Total Liabilities | $1,272,020 | $1,620,989 |
| Stockholders' Equity | $1,185,345 | $571,717 |
Key Expense Drivers (2024): Stock-based compensation ($2.65M), Professional fees ($2.76M), and Interest expense ($356k).
Debt: Notes payable decreased significantly due to conversions into equity. As of Dec 31, 2024, outstanding notes payable were $240,753 (non-related party) and $31,000 (related party).
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased by approximately $5.44 million (867% increase) year-over-year. This was primarily driven by a $2.65 million stock-based compensation expense and increased professional fees related to the business combination and public company compliance.
- Business Combination: Completed the merger with Redwoods Acquisition Corp. in June 2024. The transaction was treated as a reverse acquisition. The company received approximately $1.13 million in net cash proceeds from PIPE financing and the merger, though a significant portion was used to settle transaction costs.
- Capital Structure: Significant issuance of common stock occurred in 2024, including shares issued for the conversion of convertible promissory notes ($4.01M principal converted) and stock-based compensation awards. Outstanding shares increased from ~15.1 million (2023) to ~27.1 million (2024).
- Intangible Assets: Acquired a drug license for $123,497 in 2024. Recognized a $10,000 impairment charge on a terminated license agreement with Teleost Biopharmaceutic, LLC.
Guidance, Outlook, Risks, and Contingencies
Outlook and Liquidity: The company has a "substantial doubt" regarding its ability to continue as a going concern. With only $63,741 in cash as of December 31, 2024, and an accumulated deficit of $10.6 million, the company requires significant additional funding to execute its business plans. Management plans to raise capital through equity or debt securities.
Development Pipeline:
- KLTO-202 (ALS): Plans to complete animal toxicology and submit an Investigational New Drug (IND) application to the FDA in 2025 for a Phase I "Compassionate Use" study.
- KLTO-101 (Alzheimer's): Pre-clinical development is expected to follow KLTO-202 by 6-9 months. Seeking a corporate partner for development.
- Biosimilars: Preparing for Phase 3 clinical trials for bevacizumab-anew and rituximab-anew.
Material Risks:
- Nasdaq Delisting: The company received notices in August and October 2024 for failing to meet minimum market value and minimum bid price requirements. While granted an extension to regain compliance by February 12, 2025, the company faces potential delisting if it fails to meet standards. A subsequent event (March 2025) indicates a hearing was held, and listing was continued subject to completing an acquisition by August 13, 2025.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting due to inadequate accounting resources and lack of segregation of duties.
- Regulatory Approval: No products are currently approved for commercial sale. Success depends on regulatory approvals which are uncertain, time-consuming, and costly.
- Intellectual Property: Reliance on third-party licenses (UAB, Reliance Life Sciences) involves significant milestone payments and royalties that may be due before revenue is generated.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $63,741 cash balance against current burn rates and the timeline for the next capital raise.
- Nasdaq Compliance: Confirm the status of the Nasdaq listing extension and the progress of the proposed acquisition of SB Security Holdings, LLC (announced March 2025) which is a condition for continued listing.
- Going Concern Status: Review the auditor's report and management's discussion on the "substantial doubt" regarding the company's ability to continue operations without new financing.
- Internal Controls: Assess the remediation plan for the identified material weaknesses in internal controls over financial reporting.
- Debt Conversions: Verify the terms and dilution impact of the convertible promissory notes issued in late 2024 and early 2025 (e.g., Austria Capital LLC, Red Road Holdings, and the January 2025 Institutional Investor agreement).
- Pipeline Milestones: Monitor the submission of the IND for KLTO-202 in 2025 and the associated costs.